Under the rule, the list price for drugs or biologics must be included if the price exceeds $35 for a month’s supply or the usual course of therapy. The benchmark $35 is a common patient monthly co-payment.
The rule requires the pricing information to be in text large enough for most people to read. It also allows companies to include list prices of competitor products and a statement that patients with health insurance may pay a different sum.
The rule will take effect in about 60 days. It was initially proposed as part of President Donald Trump’s “blueprint” to lower drug prices in the U.S.
Including list prices in TV ads could discourage patients from seeking medical care, the Pharmaceutical Research and Manufacturers of America said.
More articles on pharmacy:
Insys execs guilty of opioid racketeering scheme
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody’s says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
